151 related articles for article (PubMed ID: 11358812)
1. A polymorphism in CYP17 and endometrial cancer risk.
Haiman CA; Hankinson SE; Colditz GA; Hunter DJ; De Vivo I
Cancer Res; 2001 May; 61(10):3955-60. PubMed ID: 11358812
[TBL] [Abstract][Full Text] [Related]
2. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
Haiman CA; Hankinson SE; Spiegelman D; Colditz GA; Willett WC; Speizer FE; Kelsey KT; Hunter DJ
Cancer Res; 1999 Mar; 59(5):1015-20. PubMed ID: 10070957
[TBL] [Abstract][Full Text] [Related]
3. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
[TBL] [Abstract][Full Text] [Related]
4. CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.
Verla-Tebit E; Wang-Gohrke S; Chang-Claude J
Breast Cancer Res; 2005; 7(4):R455-64. PubMed ID: 15987450
[TBL] [Abstract][Full Text] [Related]
5. CYP17 genetic polymorphism in endometrial cancer: are only steroids involved?
Berstein LM; Imyanitov EN; Gamajunova VB; Kovalevskij AJ; Kuligina ESh; Belogubova EV; Buslov KG; Karpova MB; Togo AV; Volkov ON; Kovalenko IG
Cancer Lett; 2002 Jun; 180(1):47-53. PubMed ID: 11911969
[TBL] [Abstract][Full Text] [Related]
6. CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity.
Berstein LM; Imyanitov EN; Kovalevskij AJ; Maximov SJ; Vasilyev DA; Buslov KG; Sokolenko AP; Iyevleva AG; Chekmariova EV; Thijssen JH
Cancer Lett; 2004 Apr; 207(2):191-6. PubMed ID: 15072828
[TBL] [Abstract][Full Text] [Related]
7. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors.
Ambrosone CB; Moysich KB; Furberg H; Freudenheim JL; Bowman ED; Ahmed S; Graham S; Vena JE; Shields PG
Breast Cancer Res; 2003; 5(2):R45-51. PubMed ID: 12631398
[TBL] [Abstract][Full Text] [Related]
8. Association between the T27C polymorphism in the cytochrome P450 c17alpha (CYP17) gene and risk factors for breast cancer.
Hong CC; Thompson HJ; Jiang C; Hammond GL; Tritchler D; Yaffe M; Boyd NF
Breast Cancer Res Treat; 2004 Dec; 88(3):217-30. PubMed ID: 15609124
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation in CYP17 and endometrial cancer risk.
Gaudet MM; Lacey JV; Lissowska J; Peplonska B; Brinton LA; Chanock S; Garcia-Closas M
Hum Genet; 2008 Mar; 123(2):155-62. PubMed ID: 18172694
[TBL] [Abstract][Full Text] [Related]
10. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype.
McKean-Cowdin R; Feigelson HS; Pike MC; Coetzee GA; Kolonel LN; Henderson BE
Cancer Res; 2001 Feb; 61(3):848-9. PubMed ID: 11221867
[TBL] [Abstract][Full Text] [Related]
11. [A case-control study on genetic polymorphism of CYP17 MspA(1)I and its association with endometrial cancer risk].
Gao J; Xiang YB; Xu WH; Cheng JR; Cai QY; Shu XO; Gao YT
Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):266-9. PubMed ID: 17760252
[TBL] [Abstract][Full Text] [Related]
12. [Genetic polymorphism of steroid 17 alpha-hydroxylase/17,20-lyase (CYP17) and hyperinsulinemia in endometrial carcinoma].
Berstein LM; Imianitov EN; Gamaiunova VB; Kovalevskiĭ AIu; Kuligina ESh; Belogubova EV; Buslov KG; Karpova MB; Togo AV; Volkov ON; Kovalenko IG; Chernobrovkina AE
Vopr Onkol; 2002; 48(6):673-8. PubMed ID: 12530262
[TBL] [Abstract][Full Text] [Related]
13. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.
Ye Z; Parry JM
Mutagenesis; 2002 Mar; 17(2):119-26. PubMed ID: 11880540
[TBL] [Abstract][Full Text] [Related]
14. A polymorphism in the CYP17 gene and risk of prostate cancer.
Stanford JL; Noonan EA; Iwasaki L; Kolb S; Chadwick RB; Feng Z; Ostrander EA
Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):243-7. PubMed ID: 11895872
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphism of CYP17 and breast cancer risk in Korean women.
Shin MH; Lee KM; Yang JH; Nam SJ; Kim JW; Yoo KY; Park SK; Noh DY; Ahn SH; Kim B; Kang D
Exp Mol Med; 2005 Feb; 37(1):11-7. PubMed ID: 15761247
[TBL] [Abstract][Full Text] [Related]
16. Association between CYP17 polymorphisms and the development of breast cancer.
Helzlsouer KJ; Huang HY; Strickland PT; Hoffman S; Alberg AJ; Comstock GW; Bell DA
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):945-9. PubMed ID: 9796641
[TBL] [Abstract][Full Text] [Related]
17. A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss.
Sata F; Yamada H; Yamada A; Kato EH; Kataoka S; Saijo Y; Kondo T; Tamaki J; Minakami H; Kishi R
Mol Hum Reprod; 2003 Nov; 9(11):725-8. PubMed ID: 14561815
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy.
Feigelson HS; McKean-Cowdin R; Pike MC; Coetzee GA; Kolonel LN; Nomura AM; Le Marchand L; Henderson BE
Cancer Res; 1999 Aug; 59(16):3908-10. PubMed ID: 10463580
[TBL] [Abstract][Full Text] [Related]
20. CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer.
Aban M; Arslan M; Tok E; Tekes S; Budak T; Altintas A
Int J Gynecol Cancer; 2006; 16 Suppl 1():448-51. PubMed ID: 16515644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
